Chronic Pruritus: A Review

• Published in: JAMA : the journal of the American Medical Association 2024-06, Vol.331 (24), p.2114-2124
• Main Authors: Butler, Daniel C, Berger, Timothy, Elmariah, Sarina, Kim, Brian, Chisolm, Sarah, Kwatra, Shawn G, Mollanazar, Nicholas, Yosipovitch, Gil
• Format: Article
• Language: English
• Subjects: Antidepressants; Blood cells; Butorphanol; Chronic Disease; Dermatitis; Dermatology; Eczema; Effectiveness; Etiology; Gabapentin; Hepatocytes; Humans; Hydrocortisone; Immunomodulation; Immunotherapy; Kidney diseases; Lidocaine; Liver diseases; Malignancy; Menthol; Methotrexate; Neuralgia; Opioid receptors; Patients; Pruritus; Pruritus - drug therapy; Pruritus - etiology; Psoriasis; Quality of life; Scabies; Seborrheic dermatitis; Signs and symptoms; Skin diseases; Steroid hormones; Steroids; Tacrolimus; Thyroid; Thyroid diseases; Thyroid gland
• ISSN: 0098-7484; 1538-3598; 1538-3598
• DOI: 10.1001/jama.2024.4899

IMPORTANCE: Chronic pruritus, defined as itch experienced for 6 weeks or longer, affects approximately 22% of people in their lifetime. Approximately 1% of physician visits are for the chief concern of chronic pruritus. Chronic pruritus is associated with adverse outcomes, including impaired sleep and reduced quality of life. OBSERVATIONS: Chronic pruritus can be categorized by etiology into inflammatory, neuropathic, or a combination of inflammatory and neuropathic pruritus. Chronic pruritus is due to inflammation in approximately 60% of patients and may be caused by eczema, psoriasis, or seborrheic dermatitis. Chronic pruritus is due to a neuropathic or mixed etiology in approximately 25% of patients. Neuropathic causes of chronic pruritus include postherpetic neuralgia and notalgia paresthetica and are typically due to localized or generalized nerve dysregulation. Approximately 15% of people with chronic pruritus have other causes including systemic diseases with secondary itch, such as uremic pruritus and cholestatic pruritus, medication-induced pruritus such as pruritus due to immunotherapy, and infectious etiologies such as tinea corporis and scabies. When few primary changes are present, a thorough history, review of symptoms, and laboratory evaluation should be performed, particularly for people with chronic pruritus lasting less than 1 year. Clinicians should consider the following tests: complete blood cell count, complete metabolic panel, and thyroid function testing to evaluate for hematologic malignancy, liver disease, kidney disease, or thyroid disease. First-line treatment for inflammatory chronic pruritus includes topical anti-inflammatory therapies such as hydrocortisone (2.5%), triamcinolone (0.1%), or tacrolimus ointment. Approximately 10% of patients do not respond to topical therapies. In these patients, referral to dermatology and systemic oral or injectable treatments such as dupilumab or methotrexate may be considered. When no underlying systemic disease associated with pruritus is identified, patients are likely to have neuropathic chronic pruritus or mixed etiology such as chronic pruritus of unknown origin. In these patients, neuropathic topical treatments such as menthol, pramoxine, or lidocaine can be used either alone or in combination with immunomodulatory agents such as topical steroids. Other effective therapies for neuropathic pruritus include gabapentin, antidepressants such as sertraline or doxepin, or opioid receptor ag